Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
CJC-1295 vs GHRP-6
An educational, source-based comparison of CJC-1295 and GHRP-6 — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic analog of growth hormone-releasing hormone (GHRH). The non-DAC version has a short half-life that preserves pulsatile GH release, while DAC variants extend the half-life via albumin binding. Research focuses on stimulating endogenous GH and IGF-1 production via the pituitary.
- Endogenous GH pulse amplitude
- IGF-1 elevation
- Body composition in adult GH-deficient research
- Sleep architecture (slow-wave sleep)
- • GH-axis manipulation may affect glucose tolerance.
- • Banned in competitive sport (WADA).
- • Requires physician oversight in any therapeutic context.
A hexapeptide ghrelin receptor (GHS-R1a) agonist that stimulates pituitary GH release and increases appetite via central ghrelin pathways. One of the earliest GH-releasing peptides studied.
- Endogenous GH pulse stimulation
- Appetite stimulation in cachexia models
- Cardioprotective signaling (preclinical)
- • Increases appetite and may elevate cortisol/prolactin more than newer secretagogues.
- • Not FDA-approved; banned by WADA.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Two cited studies; independent replication needed.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| CJC-1295 | Sustained pharmacological GH activity in healthy adults via DAC technology | Journal of Clinical Endocrinology & Metabolism | 2006 | Established prolonged GH/IGF-1 elevation from single subcutaneous doses. |
| CJC-1295 | GHRH analogs and the GH-IGF-1 axis | Endocrine Reviews | 2011 | Mechanistic review of GHRH-analog pharmacology. |
| GHRP-6 | GHRP-6 and the ghrelin receptor: cardiometabolic effects | Cardiovascular Research | 2010 | Review of GH-independent cardioprotective signaling observed in animal models. |
Side-effect & safety grid
- GH-axis manipulation may affect glucose tolerance.
- Banned in competitive sport (WADA).
- Requires physician oversight in any therapeutic context.
- Increases appetite and may elevate cortisol/prolactin more than newer secretagogues.
- Not FDA-approved; banned by WADA.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
CJC-1295 vs GHRP-6 — Key differences
- Class: CJC-1295 is classified as Growth Hormone Axis, while GHRP-6 is Growth Hormone Axis.
- Primary research focus: CJC-1295 — endogenous gh pulse amplitude; GHRP-6 — endogenous gh pulse stimulation.
- Tag: Growth hormone vs Growth hormone · Appetite.